Beyond Borders: Global biotechnology report 2010

More documents

Recommendations

Info

Contents The new normal: the global perspective 2 Global introduction The new normal 7 Perspectives for the new normal Asset-centric financing Francesco De Rubertis and Michèle Ollier, Index Ventures 9 Perspectives for the new normal Lean proof of concept Michael Clayman, Flexion Therapeutics 12 A closer look Reforming US health care Connie Austin, Ernst & Young LLP 14 Perspectives for the new normal Focus and leverage Edward Lanphier, Sangamo BioSciences 16 Perspectives for the new normal Succeeding together Leonard Schleifer, Regeneron Pharmaceuticals 17 Perspectives for the new normal Efficiency and leverage John Maraganore, Alnylam Pharmaceuticals 20 Perspectives for the new normal There's gold in those efficiencies Werner Lanthaler, Evotec AG 21 Bioech innovation and the role of public policy James Greenwood, Biotechnology Industry Organization 22 Using FIPNet to supercharge the innovation engine John Lechleiter, Eli Lilly and Company New opportunities: country profiles 26 Conversation on emerging markets New opportunities Kiran Mazumdar-Shaw, Biocon Canwen Jiang, Genzyme 30 China year in review Accelerating reforms 31 A closer look Providing incentives to encourage continuous quality improvement Cherrie Che, Ernst & Young Advisory Services Ltd 36 India year in review Preparing for the opportunities ahead 39 Japan year in review Rekindling investment 41 A closer look Funding innovation Yuji Anzai, Ernst & Young Shin Nihon LLC 43 Singapore year in review Manufacturing a biopharmaceutical hub 45 New Zealand year in review A new pragmatism 47 Brazil year in review Fueling the future 50 Malaysia year in review A strategic focus on biotech
A transformational year: industry performance 54 Financial performance A transformational year • United States • Europe • Canada • Australia 55 A closer look Seeking efficiency: considerations when operating beyond borders Bruce Bouchard, Ernst & Young LLP 63 Venturing forth with creative approaches Søren Carlsen, Novo Ventures 64 Financing A higher bar • United States • Europe • Canada • Australia 68 A closer look Anatomy of a private equity IPO Michael Constantino, Ernst & Young LLP 74 A closer look Tapping economic development incentives Ron Xavier, Ernst & Young LLP 75 Turbulent financial markets and the impact on biotech Fred Frank, Peter J Solomon Company 76 Deals A new landscape • United States • Europe • Canada • Australia 79 A closer look Valuing milestones Michelle Mittelsteadt, Ernst & Young LLP 85 Striking a healthy balance Dan Zabrowski, Roche 86 92 96 98 Products and pipeline Steady growth • United States • Europe A closer look Uncertain by design: preparing for outcomes-based pricing arrangements Anthony Masherelli, Ernst & Young LLP Perspectives on personalized medicine What one thing would you change to accelerate the adoption of personalized medicine? • Edward Abrahams, Personalized Medicine Coalition • Ken Berlin, Rosetta Genomics Ltd. • Anne Wojcicki, 23andMe • Kathy Giusti, Multiple Myeloma Research Foundation/Multiple Myeloma Research Consortium • Brook Byers, Kleiner Perkins Caufield & Byers • Jay Wohlgemuth, Quest Diagnostics • Robert Epstein, Medco • Steven Averbuch, Bristol-Myers Squibb Roundtable on biofuels Embracing the future • Gil Forer, Ernst & Young LLP • Mark Bandak, Blackstone Advisory Partners • Olivier Mace, BP Biofuels • Bill Haywood, LS9 • William Roe, Coskata 103 Acknowledgments 104 Data exhibit index 106 Global biotechnology contacts 108 Ernst & Young thought leadership
Page 1: Beyond borders Global biotechnology
Page 6 and 7: The new normal
Page 8 and 9: Global introduction The new normal
Page 10 and 11: Of course, this is not a novel deve
Page 12 and 13: “Since by definition, increasing
Page 14 and 15: In both of these models, investors
Page 16 and 17: “For most of the history of the b
Page 18 and 19: A closer look Reforming US health c
Page 20 and 21: Perspectives for the new normal Foc
Page 22 and 23: Perspectives for the new normal Suc
Page 24 and 25: John Maraganore of Alnylam Pharmace
Page 26 and 27: Perspectives for the new normal The
Page 28 and 29: Using FIPNet to supercharge the inn
Page 30 and 31: New opportunities 24 Beyond borders
Page 32 and 33: Conversation on emerging markets Ne
Page 34 and 35: “The biggest challenge for Wester
Page 36 and 37: China year in review Accelerating r
Page 38 and 39: addition, the Government committed
Page 40 and 41: In 2009, overseas-listed Chinese bi
Page 42 and 43: India year in review Preparing for
Page 44 and 45: acquired US-based hybrid sorghum se
Page 46 and 47: Japanese biotech IPOs, 2009 Company
Page 48 and 49: drug application for Lurasidone to
Page 50 and 51: The year saw some examples of globa
Page 52 and 53: of today’s increasingly pragmatic
Page 54 and 55:
Biotech will provide the technology
Page 56 and 57:
Malaysia year in review A strategic
Page 58 and 59:
A transformational year 52 Beyond b
Page 60 and 61:
Financial performance A transformat
Page 62 and 63:
explained by developments at a few
Page 64 and 65:
Selected 2009 US biotechnology publ
Page 66 and 67:
Growth rate Canada Behind the numbe
Page 68 and 69:
Australian biotechnology at a glanc
Page 70 and 71:
Financing A higher bar After a dism
Page 72 and 73:
the pharmaceutical industry, as pha
Page 74 and 75:
The final 2009 IPO to close in the
Page 76 and 77:
The IPO market in Europe remains la
Page 78 and 79:
Capital raised by Canadian province
Page 80 and 81:
developed countries — and whether
Page 82 and 83:
Deals A new landscape Given the rea
Page 84 and 85:
companies will not make any large u
Page 86 and 87:
with Elan (the judge agreed) the pa
Page 88 and 89:
Without Roche-Genentech, the value
Page 90 and 91:
total potential value of these tran
Page 92 and 93:
Products and pipeline Steady growth
Page 94 and 95:
FDA product approvals, 1996-2009 Nu
Page 96 and 97:
European Phase III pipeline by indi
Page 98 and 99:
A closer look Uncertain by design:
Page 100 and 101:
oral anti-diabetes medications Janu
Page 102 and 103:
Perspectives on personalized medici
Page 104 and 105:
Moderated by: Gil Forer Ernst & You
Page 106 and 107:
“I’m starting to see non-tradit
Page 108 and 109:
from infrastructure funds, but they
Page 110 and 111:
Data exhibit index 2 The not-quite-
Page 112 and 113:
Global biotechnology contacts Globa
Page 114:
Ernst & Young thought leadership Wa
show all

Beyond Borders: Global biotechnology report 2010

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?